Rate My Professor Andrew Toner

AT

Andrew Toner

University of Western Australia

4.60/5 · 5 reviews
5 Star3
4 Star2
3 Star0
2 Star0
1 Star0
5.08/20/2025

Makes even the toughest topics accessible.

4.05/21/2025

Patient, kind, and always approachable.

5.03/31/2025

Makes complex topics easy to understand.

4.02/27/2025

Always fair, encouraging, and motivating.

5.02/17/2025

Always approachable and easy to talk to.

About Andrew

Dr Andrew Toner, MA BMBCh FRCA FANZCA MD(Res), serves as Adjunct Associate Professor in the UWA Medical School's Emergency Medicine division at the University of Western Australia. He is an Academic Anaesthetist and Consultant Anaesthetist at Royal Perth Hospital since 2016, Senior Clinical Lecturer at UWA, and Clinician Research Fellow funded by the Raine Medical Research Foundation and Western Australia Department of Health. Toner completed his undergraduate studies at Cambridge University, earned his medical qualification at Oxford University, undertook anaesthetic training at St. George's School of Anaesthesia in London, and obtained his Doctor of Medicine research degree from Cambridge University.

His academic interests centre on improving outcomes after high-risk surgery, preventing chronic post-surgical pain, perioperative inflammation and autonomic function, and apnoeic oxygenation. Toner has produced over 30 peer-reviewed publications, including three book chapters, two major reviews, and one editorial, with his work cited more than 1,000 times. Key publications include the highly cited 2017 systematic review and meta-analysis 'Safety of perioperative glucocorticoids in elective noncardiac surgery' in Anesthesiology; the 2021 'A pilot multicentre randomised controlled trial of lidocaine infusion in women undergoing breast cancer surgery' in Anaesthesia; the 2023 'Serum lidocaine concentrations during prolonged perioperative infusion in patients undergoing breast cancer surgery'; and the 2024 'Inflammation risk before cardiac surgery and the treatment effect of intraoperative dexamethasone'. He leads the LOLIPOP Trial, funded by $4.3 million from the Medical Research Future Fund to examine perioperative lidocaine infusions for reducing chronic pain after breast cancer surgery. Other major awards include a $342,625 Raine Clinician Research Fellowship in 2018, $69,605 from the Australia and New Zealand College of Anaesthetists for the LOLIPOP Pilot Study, and an NHMRC Investigator Grant Emerging Leadership Level 1 for research on hypoxic preconditioning to enhance physiological reserve before major surgery. Toner's contributions advance perioperative medicine and clinical trial design in anaesthesia.

Professional Email: andrew.toner@uwa.edu.au

    Rate My Professor: Andrew Toner | University of Western Australia | AcademicJobs